Lytix Biopharma AS

Company Description

Lytix Biopharma is a Phase II clinical stage drug development company with more than 20 years of preclinical and clinical research. Since June 2021 the company is listed on Euronext Growth.

Lytix has, in collaboration with world leading cancer research centers, developed a proprietary in situ vaccination technology platform providing a new class of drug candidates for the treatment of cancer. The treatment is aiming for activating the patient’s own immune system to fight the cancer.

In total this program covers a range of cancer indications, and it works both as monotherapy and in combination with immune checkpoint inhibitors (ICIs) and as adjunct to cell therapy. The ambition of the development program is to ensure that the entire potential of the technology platform will be revealed and released. To achieve this, Lytix has entered – and is prepared to enter further – into scientific, clinical and commercial collaborations worldwide.

Served Area

Worldwide